Moderna: positive opinion from EMA for COVID variant

(CercleFinance.com) - The European Medicines Agency (EMA) has given a positive opinion on the first two variant-adapted COVID-19 booster vaccines: Comirnaty and Spikevax, by BioNTech-Pfizer and Moderna respectively.


Related sources said that these positive opinions from the European Medicines Agency on the first two variant-adapted mRNA vaccines, from BioNTech-Pfizer and Moderna, are important to protect Europeans from the likely risk of waves of infections in autumn and winter. Indeed, people need to be prepared for another winter with COVID-19.

The company will now proceed with an accelerated authorisation of these vaccines to ensure that they can be deployed rapidly across the EU.

Subject to the EMA's scientific assessment, the group also expects an opinion on the adapted Omicron BA.4 and BA.5 vaccines in the coming weeks, it adds.

News of this booster jab really boosted Moderna shares yesterday, with them closing up 5% at about 139 dollars on this news.


Copyright (c) 2022 CercleFinance.com. All rights reserved.